Exogenus Therapeutics
Ana Catarina Pinto is a seasoned medical professional currently serving as the Medical Director for DU Oncology at Merck KGaA in Darmstadt, Germany, since May 2024. Pinto also contributes as an Advisory Board Member at Genotrial and serves on the Board of Exogenus Therapeutics. Prior roles include Director of Clinical Development at Pierre Fabre Group and Immatics, and ESMO Officer at the European Society for Medical Oncology, providing expertise in various oncology therapeutic areas. The medical experience is complemented by a comprehensive educational background, including an MD from Universidade do Porto and multiple qualifications in clinical oncology, pharmaceutical industry, and drug design.
This person is not in the org chart
This person is not in any teams
Exogenus Therapeutics
Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‑CoV‑2 infection. Contact us at team@exogenus-t.com